Last reviewed · How we verify

NCT05819814: PROACT 1

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health

Recruiting now NA Last updated 23 March 2026
What this trial tests

NA trial testing Disclosure of high polygenic risk result for coronary artery disease in Coronary Artery Disease in 200 participants. Currently enrolling.

Timeline
7 December 2023
Primary endpoint
1 May 2026
1 May 2027

Quick facts

Lead sponsorMassachusetts General Hospital
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeprevention
Enrollment200
Start date7 December 2023
Primary completion1 May 2026
Estimated completion1 May 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Massachusetts General Hospital

Who can join

Adults 40 to 75, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this randomized controlled trial is to assess the impact of disclosing a high polygenic risk result for coronary artery disease on change in cardiovascular health over one year.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Instability of high polygenic risk classification and mitigation by integrative scoring.
    Misra A, Truong B, Urbut SM, Sui Y, et al · · 2025 · cited 16× · PMID 39939586 · DOI 10.1038/s41467-025-56945-0
  2. Polygenic Risk Is Associated With Long-Term Coronary Plaque Progression and High-Risk Plaque.
    Nurmohamed NS, Shim I, Gaillard EL, Ibrahim S, et al · · 2024 · cited 10× · PMID 39152960 · DOI 10.1016/j.jcmg.2024.06.015
  3. Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis in the PROACT Clinical Trials.
    Abou-Karam R, Kim MS, Jemma Cho SM, Bitar F, et al · · 2026 · cited 1× · PMID 41706060 · DOI 10.1016/j.jacc.2025.12.032
  4. Breaking binary in cardiovascular disease risk prediction.
    Zhang Y, Fahed AC. · · 2025 · PMID 41776352 · DOI 10.1038/s44325-024-00041-7
  5. Unraveling the genetic blueprint of coronary artery disease: The role of polygenic risk scores in risk prediction.
    El Ghazawi A, Fahed AC, Fawaz N, Fakih Y, et al · · 2026 · PMID 41561400 · DOI 10.1016/j.ahjo.2025.100712

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other Massachusetts General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05819814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing